There are 2949 resources available
1159MO - Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE)
Presenter: Paula Jimenez Fonseca
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1166MO - Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas
Presenter: Constance Lamy
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1161MO - Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results
Presenter: Piero Ferolla
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1162MO - Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
Presenter: Marianne Pavel
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
532MO - A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour
Presenter: Ying Cheng
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
533MO - Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Presenter: Nicolas Girard
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
534MO - First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
Presenter: Noboru Yamamoto
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
535MO - BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Presenter: Juan Martin Liberal
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
536MO - A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours
Presenter: John Sarantopoulos
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
537MO - First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
Presenter: Maria Vieito Villar
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast